A novel TLR9 agonist as experimental therapy for prostate cancer

被引：0
|
作者：
Rayburn, E. R. [1 ]
Wang, H. [1 ]
Zhang, R. [1 ]
机构：
[1] Univ Alabama, Dept Pharmacol & Toxicol, Div Clin Pharmacol, Birmingham, AL USA
来源：
CHEMICO-BIOLOGICAL INTERACTIONS | 2006年 / 161卷 / 03期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：211 / 212
页数：2
相关论文
共 50 条
  • [1] Preclinical data of novel enantiomeric oligonucleotides for cancer immunotherapy: The TLR9 agonist EnanDIM
    Kapp, Kerstin
    Volz, Barbara
    Oswald, Detlef
    Wittig, Burghardt
    Schmidt, Manuel
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [2] Development of TLR9 agonists for cancer therapy
    Krieg, Arthur M.
    JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (05): : 1184 - 1194
  • [3] Development of an inhaled TLR9 agonist for the immunotherapy of lung cancer
    Gallotta, Marilena
    Assi, Hikmat
    Coffman, Robert L.
    Guiducci, Cristiana
    CANCER RESEARCH, 2017, 77
  • [4] An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy
    Zhang, Huagang
    Liu, Laibin
    Yu, Dong
    Kandimalla, Ekambar R.
    Sun, Hui Bin
    Agrawal, Sudhir
    Guha, Chandan
    PLOS ONE, 2012, 7 (05):
  • [5] Coadministration of Telomerase Genetic Vaccine and a Novel TLR9 Agonist in Nonhuman Primates
    Dharmapuri, Sridhar
    Peruzzi, Daniela
    Mennuni, Carmela
    Calvaruso, Francesco
    Giampaoli, Saverio
    Barbato, Gaetano
    Kandimalla, Ekambar R.
    Agrawal, Sudhir
    Scarselli, Elisa
    Mesiti, Giuseppe
    Ciliberto, Gennaro
    La Monica, Nicola
    Aurisicchio, Luigi
    MOLECULAR THERAPY, 2009, 17 (10) : 1804 - 1813
  • [6] Modulation of checkpoint expression in tumor microenvironment by intratumoral administration of a novel TLR9 agonist: Rationale for combination therapy
    Jiang, Wayne
    Wang, Daqing
    Zhu, Fugang
    Bhagat, Lakshmi
    DiMuzio, Jillian
    Agrawal, Sudhir
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [7] Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy
    Wang, Daqing
    Jiang, Wayne
    Zhu, Fugang
    Mao, Xianzhi
    Agrawal, Sudhir
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 53 (03) : 1193 - 1203
  • [8] Serum TLR2 and TLR9 in Prostate Cancer Patients in Relation to EBV Status
    Sikora, Dominika
    Kis, Jacek
    Stepien, Ewa
    Drop, Bartlomiej
    Polz-Dacewicz, Malgorzata
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (16)
  • [9] Antitumor activity of a synthetic agonist of TLR9 in preclinical lung cancer models.
    Wang, D.
    Yu, D.
    Kandimalla, E. R.
    Agrawal, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 117S - 117S
  • [10] TLR9 Agonist Regulates Angiogenesis and Inhibits Corneal Neovascularization
    Wu, Jiahui
    Cui, Hongping
    Dick, Andrew D.
    Liu, Lei
    AMERICAN JOURNAL OF PATHOLOGY, 2014, 184 (06): : 1900 - 1910
12345